Dong-A ST

Dong-A ST, founded in 1932, is a prominent pharmaceutical and healthcare entity based in Seoul, South Korea. The company specializes in the discovery, development, and manufacturing of diverse prescription drugs and medical devices. Key therapeutic offerings include Stillen for gastritis, Zydena for erectile dysfunction, Motilitone for functional dyspepsia, and Suganon for type 2 diabetes mellitus. Additionally, the firm has successfully developed Sivextro, an antibiotic approved by the US FDA and launched in international markets through strategic global partnerships.

The organization maintains a robust R&D division focused on oncology, specifically targeting immuno-oncology and epigenetic pipelines. With a workforce of 1,000-5,000 employees, Dong-A ST integrates advanced biotechnology into its manufacturing processes, producing a wide range of biologics and biosimilar products. The company operates from its primary facility in Seoul, leveraging its long-standing expertise to address complex medical needs across the Asia-Pacific region and beyond. Its commitment to innovation is reflected in its consistent investment in pre-clinical and clinical discovery phases.

Listed on the Korean stock exchange under the ticker KRX: 170900, the company reports annual revenue of $484.0M. As a key player in the B2B pharmaceutical sector, Dong-A ST continues to expand its global footprint through collaborative development and commercialization agreements. Meet Dong-A ST's team to learn more about the leadership driving these strategic initiatives. The firm remains dedicated to advancing healthcare solutions through rigorous scientific research and operational excellence, maintaining its position as a significant contributor to the global pharmaceutical landscape.